Clinical Trial Update: Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial of subcutaneous anifrolumab in adults with systemic lupus erythematosus. The study status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: ACTIVE_NOT_RECRUITING